Prilenia

prilenia.com

Prilenia is a clinical-stage biotech company founded in 2018, dedicated to developing novel therapeutics for neurodegenerative diseases such as Huntington's disease and amyotrophic lateral sclerosis (ALS). The company focuses on its lead product, Pridopidine, an oral sigma-1 receptor agonist currently in late-stage clinical development, which has an established safety profile. With a team of experienced scientists and drug developers, Prilenia aims to provide hope to patients and families affected by these conditions. The company operates globally with offices in the Netherlands, Israel, and the United States, and is backed by reputable investors, indicating strong market position and traction in the biotech sector.